RPG Life Sciences Q2 FY27 Revenue Rises After Deals

RPG Life Sciences reported consolidated revenue of Rs 211.64 crore for the second quarter of FY27, with acquisitions contributing to a broader operating base. Consolidated profit after tax stood at Rs 28.22 crore for the quarter, while first-half PAT was Rs 58.79 crore. The reported numbers need to be read alongside the company’s changed business base, as acquisitions can limit direct comparison with earlier periods. Separately, standalone Q2 net profit was Rs 23.3 crore, compared with Rs 36.9 crore a year earlier, indicating pressure on profit in the standalone business.

Consolidated Q2 revenue reaches Rs 211.64 crore

The company’s consolidated Q2 revenue was Rs 211.64 crore, or Rs 21,164 lakh. This was higher than consolidated revenue of Rs 195.69 crore reported in Q1 FY27. The sequential increase reflects a larger consolidated revenue base during the quarter. However, the information provided does not specify how much of the Q2 revenue came from acquired operations and how much came from the existing business. That distinction is important for assessing underlying organic growth.

Acquisitions affect year-on-year comparability

Acquisitions broadened RPG Life Sciences’ consolidated operations during the period. As a result, reported consolidated revenue and profit may not be directly comparable with earlier periods that did not include the acquired businesses for the same duration. The company partly funded acquisitions through Rs 243.30 crore of investor subscription. This funding source strengthened the capital available for the transactions, but it also makes the acquisition and integration process a key factor in evaluating future financial performance.

Standalone profit shows a year-on-year decline

Standalone Q2 net profit was Rs 23.3 crore, down from Rs 36.9 crore in the corresponding quarter a year ago. This represents a decline of about 36.9% year on year. The difference between standalone and consolidated profit highlights the importance of separating the performance of the parent entity from that of the wider group. The available information does not provide a detailed breakdown of the factors behind the standalone profit movement.

First-half PAT stands at Rs 58.79 crore

For the first half of FY27, RPG Life Sciences reported consolidated PAT of Rs 58.79 crore. Q1 FY27 had produced revenue of Rs 195.69 crore and net profit of Rs 30.8 crore, according to the latest reported quarterly data. The company had said Q1 revenue grew 15.8% year on year and net profit rose 17.0% year on year. The Q2 figures therefore follow a first quarter in which the core operating businesses recorded growth.

Q1 performance provided a stronger starting point

In Q1 FY27, domestic formulations sales rose 14.8% year on year to Rs 132.5 crore. International formulations sales increased 7.7% to Rs 35.0 crore. API sales grew 35.6% to Rs 26.6 crore, although the API business had been affected by a fire incident at one manufacturing block. Domestic formulations accounted for 68.3% of Q1 sales, underlining its importance to the company’s revenue mix.

FY26 background shows domestic formulation strength

RPG Life Sciences reported FY26 revenue of Rs 707.52 crore, up 8.3% from the previous year. EBITDA was Rs 172.7 crore and the EBITDA margin was 24.4%. Domestic formulations grew 13.8% during FY26, while international formulations declined 6.7%. The company had also stated that domestic formulations outperformed the Indian pharmaceutical market during the year.

Proposed amalgamation remains a corporate development

On September 25, 2026, RPG Life Sciences informed stock exchanges about a proposed Scheme of Amalgamation involving subsidiary RPG Active Pharma Limited and Actis Generics Private Limited. The provided information does not state the financial terms or timing for completion of the scheme. Still, the proposed amalgamation is relevant because it could further reshape the company’s group structure and reporting profile. Investors will need to track future exchange filings for formal approvals and implementation details.

What the Q2 figures mean for investors

The Q2 update presents two different signals. Consolidated revenue and PAT reflect a larger business base after acquisitions, while standalone profit declined sharply from the prior-year quarter. The data therefore places focus on the quality of earnings, the contribution from acquired entities, and the performance of domestic formulations, international formulations and APIs. The investor subscription of Rs 243.30 crore also makes capital deployment and acquisition integration relevant areas to monitor.

Key figures at a glance

Next disclosures will add operating detail

RPG Life Sciences’ board was scheduled to consider Q2 FY27 results on October 29, 2026, and the company had earlier scheduled an earnings call for October 30, 2026. Management commentary from these events may provide greater clarity on acquisition-related revenue, margins, the standalone profit decline and the proposed amalgamation. For now, the reported figures show higher consolidated revenue alongside lower standalone Q2 profit, making scope and comparability central to the assessment of the quarter.